Bioidentical Hormones Market to Soar in the Near Future Owing to Growing Consumer Adoption The increasing increase in the geriatric

The increasing increase in the geriatric population is one of the major reasons projected to drive the growth and demand for bioidentical hormones. Furthermore, increases in screening for hormonal deficit and an expansion in the patient pool are expected to drive growth in the worldwide bioidentical hormones market from 2019 to 2027. Similarly, rising consumer awareness of bioidentical hormones and an increase in the prevalence of hormonal imbalance disorders are expected to drive market expansion. Furthermore, the rise in use of medications and high expenditure on the health care are also expected to act as significant factors which will flourish the growth of the bioidentical hormones market.

The rapid rise in the awareness among consumers about bioidentical hormones and increase in the income level of women are expected to offer significant growth opportunities for the bioidentical hormones market in the forecast period of 2019 to 2027.

However, the various side effects such as weight loss and blurred vision are estimated to limit the growth of the bioidentical hormones market, whereas, the high risk of heart attack and breast cancer can challenge the growth of the bioidentical hormones market.

This bioidentical hormones market report includes information on new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, and g

Key players operating in the market are TherapeuticsMD, Inc., BioTE Medical, Defy Medical, Full Life Wellness Center, Neuva Aesthetics, and SottoPelle.

Moreover, key players in the market are focused on developing new products in order to enhance their market share. For instance, in October 2018, TherapeuticsMD, Inc. received U.S. Food and Drug Administration (FDA) approval for its first bio-identical hormone combination therapy of estradiol and progesterone, BIJUVA. The oral capsule is used for treatment of moderate to severe vasomotor symptoms due to menopause in women.